Suven Life Sciences Ltd
Serene Chambers
Road No. 5, Avenue - 7, Banjara Hills
Hyderabad
500 034
Tel: 91-40-2354-1142
Fax: 91-40-2354-1152
Website: http://www.suven.com/
Email: info@suven.com
122 articles about Suven Life Sciences Ltd
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Suven Revenue up by 40.24%; PAT up by 40.27% for quarter ended December’ 2018
2/5/2019
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
-
Suven Income at INR 2959 Mn; PAT at INR 567 Mn for the half year ended September 2018
11/14/2018
SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov’ 2018 at Hyderabad.
-
Suven Revenue up by 11.85%; PAT up by 15.38% for 9 Months Ended December' 2017
1/30/2018
The Un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30th Jan' 2018 at Hyderabad.
-
Suven Life Sciences Ltd’s Income At Rs. 1466 Mn; PAT At Rs. 295 Mn For The Quarter Ended June 2017
8/14/2017
-
Suven Life Sciences Ltd Announces Initiation Of Phase I Clinical Trial And First Dosing Of SUVN-911, A Neuronal Acetylcholine Nicotinic Receptor (Nachrs) Antagonist For Major Depressive Disorder (MDD)
5/25/2017
-
Suven Life Sciences Ltd Revenue Growth At 13.42%; PAT Up By 29.15% For The Half Year Ended Sept, 2016
11/28/2016
-
Suven Life Sciences Ltd’s Income At Rs. 1377 Mn; PAT At Rs. 326 Mn For The 1st Quarter Ended June 2016
8/10/2016
-
Suven Life Sciences Ltd Revenue Up By 49.21%; PAT Up By 83.23% For The Fourth Quarter Ended March 2016
5/27/2016
-
Suven Life Sciences Ltd Revenue Down By 4.96%; PAT Down By 28.34% For The Third Quarter Ended December, 2015
2/12/2016
-
Suven Life Sciences Ltd Revenue Growth At 15.55%; PAT Up By 22.23% For The Second Quarter Ended Sept, 2015
11/10/2015
-
Suven Life Sciences Ltd Secures Three (3) Product Patents In Canada And China
9/16/2015
-
Suven Life Sciences Ltd Secures Five (5) Product Patents In China, Israel, Mexico, Singapore And Sri Lanka
9/10/2015
-
Suven Life Sciences Ltd Release: SUVN-D4010 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 126099
9/2/2015
-
Suven Life Sciences Ltd’s Income Lower By 7.35%; PAT Up By 19.36% For The Quarter Ended June 2015
8/14/2015
-
Suven Life Sciences Ltd To Present At Alzheimer's Association International Conference (AAIC)
7/17/2015
-
Suven Life Sciences Ltd Secures 4 (Four) Product Patents For Their NCE’s In China, Mexico And South Africa
7/13/2015
-
Suven Life Sciences Ltd Secures Three (3) Product Patents In Israel, Japan And South Africa
6/30/2015
-
Suven Life Sciences Ltd Secures Three (3) Product Patents In Israel, Macau And USA
6/16/2015
-
Suven Life Sciences Ltd’s Income Increased By 3% And PAT Lower By 25% For The Year Ended March 2015
5/26/2015